FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2940011254> ?p ?o ?g. }

• W2940011254 endingPage "2128" @default.
• W2940011254 startingPage "2118" @default.
• W2940011254 abstract "Hypoxia imaging can guide tumor treatment and monitor changes in hypoxia during treatment. However, there is still no ideal hypoxia imaging agent for clinical applications. In this study, two novel 2-nitromidazole derivatives were synthesized and directly radiolabeled by [18F]FDG in high radiochemical yield and excellent radiochemical purity. Cell experiments, biodistribution, and positron emission tomography (PET) imaging studies were also conducted in mice-bearing S180 or OS732 tumors. [18F]FDG-2NNC2ON [(2R,3S,4R,E)-2-18F-fluoro-3,4,5,6-tetrahydroxyhexanal O-3-(2-(2-nitro-1H-imidazole-1-yl)ethylamino)-2-oxopropyl oxime] and [18F]FDG-2NNC5ON [(2R,3S,4R,E)-2-18F-fluoro-3,4,5,6-tetrahydroxyhexanal-O-3-(5-(2-nitro-1H-imidazole-1-yl)pentylamino)-2-oxopropyl oxime] can be cleared from the blood quickly and specifically target hypoxic tumor cells. The uptake of the probes by hypoxic cells gradually increases with time. After 4 h, the uptake value of [18F]FDG-2NNC2ON in hypoxic cells is 3.2 times higher than that in normoxia cells. In contrast, there is no difference in the uptake of [18F]FDG between hypoxic cells and normoxia cells. Biodistribution resulting from two tumor models indicate that the uptake values of the two radiotracers in the tumor are higher at 1 h than those at 2 and 4 h. At 1 and 2 h, the tumors are clearly observed on the PET images and the imaging features of [18F]FDG-2NNC5ON and [18F]FDG-2NNC2ON are distinct from those of [18F]FDG. Compared with [18F]FDG-2NNC5ON, [18F]FDG-2NNC2ON has a higher proportion of renal excretion, lower digestive tract uptake, and better imaging contrast because of its higher hydrophilicity. At 2 h, [18F]FDG-2NNC2ON shows a good tumor-to-blood (T/B) ratio, tumor-to-muscle ratio based on biodistribution (Bio-T/M ratio), and tumor-to-muscle ratio based on regions of interest on the PET images [region of interest (ROI)-T/M ratio] in the two tumor models (T/B, Bio-T/M, and ROI-T/M ratios are 3.2, 2.6, and 3.9 in the S180 tumor model and are 3.4, 4.2, and 4.6 in the OS732 tumor model, respectively). The imaging features visualized with autoradiography mostly coincided with the positive areas of HIF1α staining by immunofluorescence. Meanwhile, the biodistribution study and PET imaging revealed that the uptake of the radiotracers in the tumor cannot be competed by 5% glucose, confirming that [18F]FDG-2NNC2ON targets the hypoxic regions of the tumors instead of targeting tumors through the glucose metabolism pathway. These results suggest that the new 2-nitroimidazole derivative conjugated with [18F]FDG, [18F]FDG-2NNC2ON, has potential as an imaging agent for hypoxia." @default.
• W2940011254 created "2019-04-25" @default.
• W2940011254 creator A5023363049 @default.
• W2940011254 creator A5038836690 @default.
• W2940011254 creator A5048800314 @default.
• W2940011254 creator A5057805231 @default.
• W2940011254 creator A5064594285 @default.
• W2940011254 date "2019-04-09" @default.
• W2940011254 modified "2023-10-16" @default.
• W2940011254 title "Synthesis and Bioevaluation of Novel [¹⁸F]FDG-Conjugated 2-Nitroimidazole Derivatives for Tumor Hypoxia Imaging" @default.
• W2940011254 cites W1475316944 @default.
• W2940011254 cites W1964889885 @default.
• W2940011254 cites W1965102758 @default.
• W2940011254 cites W1976955518 @default.
• W2940011254 cites W1993480771 @default.
• W2940011254 cites W2001334218 @default.
• W2940011254 cites W2015860044 @default.
• W2940011254 cites W2018239968 @default.
• W2940011254 cites W2019586824 @default.
• W2940011254 cites W2020835690 @default.
• W2940011254 cites W2029375439 @default.
• W2940011254 cites W2045051280 @default.
• W2940011254 cites W2057148433 @default.
• W2940011254 cites W2062588170 @default.
• W2940011254 cites W2063040188 @default.
• W2940011254 cites W2063177561 @default.
• W2940011254 cites W2067534736 @default.
• W2940011254 cites W2097912113 @default.
• W2940011254 cites W2098960013 @default.
• W2940011254 cites W2100486273 @default.
• W2940011254 cites W2157607856 @default.
• W2940011254 cites W2161981534 @default.
• W2940011254 cites W2469401440 @default.
• W2940011254 cites W2593092776 @default.
• W2940011254 cites W2726654482 @default.
• W2940011254 cites W2735814828 @default.
• W2940011254 cites W2793604215 @default.
• W2940011254 cites W2801054688 @default.
• W2940011254 cites W4249593089 @default.
• W2940011254 doi "https://doi.org/10.1021/acs.molpharmaceut.9b00075" @default.
• W2940011254 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30964298" @default.
• W2940011254 hasPublicationYear "2019" @default.
• W2940011254 type Work @default.
• W2940011254 sameAs 2940011254 @default.
• W2940011254 citedByCount "12" @default.
• W2940011254 countsByYear W29400112542020 @default.
• W2940011254 countsByYear W29400112542021 @default.
• W2940011254 countsByYear W29400112542023 @default.
• W2940011254 crossrefType "journal-article" @default.
• W2940011254 hasAuthorship W2940011254A5023363049 @default.
• W2940011254 hasAuthorship W2940011254A5038836690 @default.
• W2940011254 hasAuthorship W2940011254A5048800314 @default.
• W2940011254 hasAuthorship W2940011254A5057805231 @default.
• W2940011254 hasAuthorship W2940011254A5064594285 @default.
• W2940011254 hasConcept C112613896 @default.
• W2940011254 hasConcept C126322002 @default.
• W2940011254 hasConcept C150903083 @default.
• W2940011254 hasConcept C177322064 @default.
• W2940011254 hasConcept C178790620 @default.
• W2940011254 hasConcept C185592680 @default.
• W2940011254 hasConcept C202751555 @default.
• W2940011254 hasConcept C207001950 @default.
• W2940011254 hasConcept C2775842073 @default.
• W2940011254 hasConcept C2776970183 @default.
• W2940011254 hasConcept C2777807558 @default.
• W2940011254 hasConcept C2778172261 @default.
• W2940011254 hasConcept C2779081379 @default.
• W2940011254 hasConcept C2989005 @default.
• W2940011254 hasConcept C509974204 @default.
• W2940011254 hasConcept C521977710 @default.
• W2940011254 hasConcept C540031477 @default.
• W2940011254 hasConcept C55493867 @default.
• W2940011254 hasConcept C71924100 @default.
• W2940011254 hasConcept C7836513 @default.
• W2940011254 hasConcept C86803240 @default.
• W2940011254 hasConceptScore W2940011254C112613896 @default.
• W2940011254 hasConceptScore W2940011254C126322002 @default.
• W2940011254 hasConceptScore W2940011254C150903083 @default.
• W2940011254 hasConceptScore W2940011254C177322064 @default.
• W2940011254 hasConceptScore W2940011254C178790620 @default.
• W2940011254 hasConceptScore W2940011254C185592680 @default.
• W2940011254 hasConceptScore W2940011254C202751555 @default.
• W2940011254 hasConceptScore W2940011254C207001950 @default.
• W2940011254 hasConceptScore W2940011254C2775842073 @default.
• W2940011254 hasConceptScore W2940011254C2776970183 @default.
• W2940011254 hasConceptScore W2940011254C2777807558 @default.
• W2940011254 hasConceptScore W2940011254C2778172261 @default.
• W2940011254 hasConceptScore W2940011254C2779081379 @default.
• W2940011254 hasConceptScore W2940011254C2989005 @default.
• W2940011254 hasConceptScore W2940011254C509974204 @default.
• W2940011254 hasConceptScore W2940011254C521977710 @default.
• W2940011254 hasConceptScore W2940011254C540031477 @default.
• W2940011254 hasConceptScore W2940011254C55493867 @default.
• W2940011254 hasConceptScore W2940011254C71924100 @default.
• W2940011254 hasConceptScore W2940011254C7836513 @default.
• W2940011254 hasConceptScore W2940011254C86803240 @default.
• W2940011254 hasFunder F4320321001 @default.
• W2940011254 hasFunder F4320321540 @default.

• next